Related Experiment Video
Updated: Mar 5, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Remote control of glucose homeostasis in vivo using photopharmacology
Zenobia B Mehta1, Natalie R Johnston1, Marie-Sophie Nguyen-Tu1
1Section of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, London, W12 0NN, UK.
Abstract:
Photopharmacology describes the use of light to precisely deliver drug activity in space and time. Such approaches promise to improve drug specificity by reducing off-target effects. As a proof-of-concept, we have subjected the fourth generation photoswitchable sulfonylurea JB253 to comprehensive toxicology assessment, including mutagenicity and maximum/repeated tolerated dose studies, as well as in vivo testing in rodents. Here, we show that JB253 is well-tolerated with minimal mutagenicity and can be used to optically-control glucose homeostasis in anesthetized mice following delivery of blue light to the pancreas. These studies provide the first demonstration that photopharmacology may one day be applicable to the light-guided treatment of type 2 diabetes and other metabolic disease states in vivo in humans.
Insights
Photopharmacology uses light to control drug activity, improving specificity. A new drug, JB253, shows promise for optically controlling glucose in mice, suggesting future diabetes treatments.
Area of Science:
- Pharmacology
- Biomedical Engineering
- Endocrinology
Background:
- Photopharmacology offers precise spatiotemporal control of drug activity.
- This approach aims to enhance drug specificity and minimize off-target effects.
- Current treatments for metabolic diseases lack precise control mechanisms.
Purpose of the Study:
- To assess the toxicology and in vivo efficacy of the photoswitchable sulfonylurea JB253.
- To demonstrate the potential of photopharmacology in managing metabolic homeostasis.
- To evaluate JB253 as a potential therapeutic agent for type 2 diabetes.
Main Methods:
- Comprehensive toxicology assessment of JB253, including mutagenicity and dose-ranging studies.
- In vivo testing in rodent models to evaluate drug tolerability and efficacy.
- Optical control of glucose homeostasis using blue light delivered to the pancreas.
Main Results:
- JB253 demonstrated good tolerability with minimal mutagenicity in toxicology studies.
- Blue light delivery to the pancreas successfully controlled glucose homeostasis in anesthetized mice.
- The photoswitchable drug JB253 showed efficacy in an in vivo model.
Conclusions:
- JB253 is a well-tolerated photoswitchable compound with potential for therapeutic applications.
- Photopharmacology using JB253 offers a novel strategy for optically controlling glucose homeostasis.
- These findings support the potential application of photopharmacology in treating type 2 diabetes and other metabolic disorders.
More Related Videos
Related Concept Videos
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...

